Vineet Laboratories Ltd

Vineet Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with the most recent insights into the company's performance and outlook.

At Rs 37.2, sellers were still queuing — but there were no buyers willing to take the other side. Vineet Laboratories Ltd locked at its lower circuit of 3.5% on 30 Apr 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock with limited liquidity.

Vineet Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 24 April 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market standing.

Vineet Laboratories Ltd has reached a significant milestone by touching a new 52-week high of Rs.43.56 on 24 Apr 2026, marking a continuation of its strong upward momentum amid a challenging broader market environment.

At Rs 43.45, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vineet Laboratories Ltd locked at its upper circuit of 20% on 20 Apr 2026, with buyers queuing and no sellers willing to part with shares.

With a decisive surge to Rs 43.52 on 21 Apr 2026, Vineet Laboratories Ltd has reached a fresh 52-week high, marking a remarkable 74.36% gain over the past year. This rally is underscored by a strong alignment of technical indicators and sustained price momentum, setting the stock apart in the Pharmaceuticals & Biotechnology sector.

Vineet Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Vineet Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026, reflecting a nuanced shift in its market standing. While the company continues to grapple with weak financial fundamentals and valuation concerns, improvements in technical indicators have prompted a more favourable outlook from analysts. This article examines the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.

Vineet Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 24 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Vineet Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 March 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s technical trend has improved to mildly bullish, prompting a reassessment of its outlook, even as financial performance remains flat and profitability metrics continue to disappoint.

Vineet Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 10 March 2026, reflecting deteriorating technical indicators and weak fundamental performance. The downgrade is driven by a combination of sideways technical trends, poor financial results, unfavourable valuation metrics, and declining quality scores, signalling heightened risk for investors in this Pharmaceuticals & Biotechnology stock.

Vineet Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Vineet Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Vineet Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 6 February 2026, reflecting deteriorating fundamentals, challenging valuation metrics, a negative financial trend, and mixed technical signals. The pharmaceutical company’s recent performance and outlook have raised concerns among analysts, prompting a reassessment of its investment appeal.

Vineet Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 February 2026, driven primarily by a marked improvement in technical indicators. However, the company continues to face significant challenges on the fundamental and financial fronts, with deteriorating profitability and weak long-term growth prospects weighing heavily on investor sentiment.

Vineet Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 25 January 2026, providing investors with the latest insights into its performance and outlook.